The Crohn’s disease therapeutics market was valued at USD 11.59 Billion in 2024, driven by the rising prevalence of Crohn’s disease across the 8 major markets. The market is anticipated to grow at a CAGR of 3.70% during the forecast period of 2025-2034, with the values likely to reach USD 16.67 Billion by 2034.
Base Year
Historical Period
Forecast Period
The market is expected to grow due to the rising incidence of inflammatory bowel diseases and advancements in biologic treatments targeting immune responses.
Increased investment in research and development is driving innovation, particularly in targeted therapies and personalized medicine, offering hope for more effective treatments for Crohn’s disease.
The growing preference for biologics over traditional therapies is poised to fuel market growth, with a focus on improving patient outcomes and reducing side effects associated with long-term treatments.
Crohn’s disease is a chronic inflammatory bowel disease (IBD) that causes inflammation of the digestive tract, leading to symptoms such as abdominal pain, diarrhea, fatigue, and weight loss. The condition can occur anywhere in the gastrointestinal tract. Therapeutics include anti-inflammatory drugs, immunosuppressants, biologics, and surgical interventions, aiming to manage symptoms, reduce inflammation, and improve quality of life.
Surge in Clinical Trials to Boost Market Growth
The increasing demand for novel, targeted therapies and the rise in Crohn’s disease prevalence are significant drivers for the market. For instance, in October 2024, Abivax SA announced the enrolment of the first patient in its Phase 2b ENHANCE-CD trial to evaluate obefazimod in patients with moderate to severe Crohn's disease. This trial, focusing on induction and maintenance therapy, aims to assess the drug’s efficacy and safety. Obefazimod could offer a new oral treatment for patients who have not responded to conventional therapies. The positive results from this trial would significantly impact the market by providing an additional effective therapy option, driving growth in the coming years.
Growth in Approvals from Regulatory Authorities to Meet Increasing Crohn’s Disease Therapeutics Market Demand
The rising demand for affordable biologics and increased healthcare accessibility are accelerating the growth of biosimilar products. For instance, in December 2024, Biocon Biologics received US FDA approval to launch its biosimilar version of Janssen’s Stelara (Ustekinumab) for autoimmune disorders, including Crohn’s disease. With the approval of its biosimilar, Yesintek, Biocon is poised to compete with established brands in the market. The upcoming launch of this biosimilar, expected by February 2025, will likely reduce treatment costs and increase market access for Crohn's disease therapies, fostering competitive pricing and growth in the therapeutic market during the forecast period.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
Market Breakup by Type
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Region
Ileocolitis is expected to hold the largest market share in the forecast period. The market share can be attributed to its higher prevalence, affecting both the ileum and colon. This form is more commonly diagnosed, leading to a greater demand for therapies focused on managing inflammation, controlling symptoms, and preventing flare-ups, contributing to its dominant position in the market.
The United States holds the largest market share for Crohn’s disease therapeutics due to high disease prevalence, advanced healthcare infrastructure, and strong access to innovative biologic treatments. The presence of leading pharmaceutical companies and increasing demand for personalised therapies further contribute to the region’s dominance in the market.
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Takeda Pharmaceutical Company Limited, headquartered in Tokyo, Japan, was established in 1781. The company is a global leader in immunology and gastroenterology, focusing on inflammatory bowel diseases, including Crohn's disease. Takeda's portfolio includes Entyvio (vedolizumab), a biologic approved for treating moderate-to-severe Crohn's disease, and other therapies aimed at improving patient outcomes in gastrointestinal disorders.
AbbVie Inc., founded in 2013 and headquartered in North Chicago, USA, is a global biopharmaceutical company. AbbVie's portfolio in the Crohn's disease therapeutics market includes Humira (adalimumab), a widely used biologic, and Rinvoq (upadacitinib), an oral therapy. The company focuses on immunology treatments, including for inflammatory bowel diseases like Crohn's disease.
Pfizer Inc., established in 1849 and headquartered in New York, USA, is a multinational biopharmaceutical company. Pfizer offers innovative treatments for Crohn's disease, such as Xeljanz (tofacitinib), an oral Janus kinase (JAK) inhibitor. The company continues to develop therapies targeting immune-mediated diseases, enhancing the options for Crohn's disease management.
Ferring B.V., based in Saint-Prex, Switzerland, was founded in 1950. The company focuses on biopharmaceuticals in gastroenterology and reproductive health. Ferring's portfolio in Crohn's disease includes products like Revestive (teduglutide), used for short bowel syndrome, a complication associated with Crohn’s disease, and other treatments aimed at improving gastrointestinal health.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, UCB S.A., Salix Pharmaceuticals, and Gilead Sciences Inc.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
